Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase EARLY_PHASE1 1Phase 3 1Phase 2 1

Status

Completed 4Unknown 2Recruiting 2Not yet recruiting 2Withdrawn 1Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 413Carcinoma, Non-Small-Cell Lung 286Prostatic Neoplasms 208Neoplasms 204Neoplasm Metastasis 180Melanoma 164Multiple Myeloma 158Colorectal Neoplasms 158Leukemia, Myeloid, Acute 143Lung Neoplasms 132Leukemia 126Lymphoma 118Pancreatic Neoplasms 117Recurrence 111Ovarian Neoplasms 111Leukemia, Lymphocytic, Chronic, B-Cell 110Lymphoma, Non-Hodgkin 105Carcinoma, Renal Cell 104Brain Neoplasms 90Myelodysplastic Syndromes 88Precursor Cell Lymphoblastic Leukemia-Lymphoma 86Glioblastoma 85Lymphoma, Large B-Cell, Diffuse 80Lymphoma, Follicular 79Carcinoma, Hepatocellular 79Head and Neck Neoplasms 77Squamous Cell Carcinoma of Head and Neck 76Urinary Bladder Neoplasms 66Stomach Neoplasms 61Hodgkin Disease 60

Interventions

folfirinox 1Radiotherapy 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Terminated × Carcinoma, Pancreatic Ductal × Clear all
NCT02243007 2017-05-16

Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer

Massachusetts General Hospital

Phase 2 Terminated
7 enrolled 8 charts
Gastrointestinal

Carcinoma, Pancreatic Ductal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡